{"doc_id": "33429174", "type of study": "Therapy", "title": "", "abstract": "Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial.\nTo evaluate the role of the topical corticosteroid, mometasone furoate, nasal spray in the treatment of post COVID-19 anosmia.\nA prospective, randomized, controlled trial was conducted among patients with post COVID-19 anosmia.\nOne hundred patients were randomly assigned to two groups; group I included 50 patients received mometasone furoate nasal spray in an appropriate dose of 2 puff (100\u00a0\u03bcg) once daily in each nostril for 3\u00a0weeks with olfactory training, group II included 50 patients were advised to keep on olfactory training only.\nThe assessment of smell was done using (Visual Analog Scale from 0 to 10).\nAll patients were initially evaluated after their recovery from COVID-19 and followed up for 3\u00a0weeks.\nThe smell scores were recorded weekly and the duration of smell loss was recorded from the onset of anosmia till the full recovery.\nIn both groups, the smell scores significantly improved by the end of the third week (P < 0.001).\nBy comparing smell scores between both groups after 1\u00a0week, 2\u00a0weeks, and 3\u00a0weeks of treatment, there were no statistically significant differences between both groups.\nIn group I, (62%) of patients completely recovered their sense of smell after 3\u00a0weeks of treatment, compared to (52%) of patients in group II (P = 0.31).\nThe results suggested that using mometasone furoate nasal spray as a topical corticosteroid in the treatment of post COVID-19 anosmia offers no superiority benefits over the olfactory training, regarding smell scores, duration of anosmia, and recovery rates.\nTRIAL REGISTRATION : ClinicalTrials.gov ID: NCT04484493.\nCopyright \u00a9 2021 Elsevier Inc. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 70}, {"term": "post", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 110}, {"term": "post", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 84}, {"term": "post COVID-19 anosmia", "negation": "affirmed", "UMLS": {}, "start": 112, "end": 133}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients : A randomized controlled trial .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 70}], "Intervention": [{"term": "Corticosteroid nasal spray", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 26}], "Outcome": [{"term": "recovery of smell sensation", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 58}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVES", "Text": "To evaluate the role of the topical corticosteroid , mometasone furoate , nasal spray in the treatment of post COVID-19 anosmia .", "Evidence Elements": {"Participant": [{"term": "post", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 110}], "Intervention": [{"term": "topical corticosteroid", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 50}, {"term": "mometasone furoate", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 71}, {"term": "nasal spray", "negation": "affirmed", "UMLS": {}, "start": 74, "end": 85}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "A prospective , randomized , controlled trial was conducted among patients with post COVID-19 anosmia .", "Evidence Elements": {"Participant": [{"term": "post", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 84}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "One hundred patients were randomly assigned to two groups ; group I included 50 patients received mometasone furoate nasal spray in an appropriate dose of 2 puff ( 100 \u03bcg ) once daily in each nostril for 3 weeks with olfactory training , group II included 50 patients were advised to keep on olfactory training only .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "mometasone furoate nasal spray in an appropriate dose of 2 puff", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 161}, {"term": "olfactory training", "negation": "affirmed", "UMLS": {}, "start": 217, "end": 235}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The assessment of smell was done using ( Visual Analog Scale from 0 to 10 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "smell", "negation": "affirmed", "UMLS": {}, "start": 18, "end": 23}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "All patients were initially evaluated after their recovery from COVID-19 and followed up for 3 weeks .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The smell scores were recorded weekly and the duration of smell loss was recorded from the onset of anosmia till the full recovery .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "smell scores", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 16}, {"term": "duration of smell loss", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 68}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "In both groups , the smell scores significantly improved by the end of the third week ( P < 0.001 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "both groups", "negation": "affirmed", "UMLS": {}, "start": 3, "end": 14}], "Outcome": [{"term": "smell scores", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 33}], "Observation": [{"term": "significantly improved", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 56}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "By comparing smell scores between both groups after 1 week , 2 weeks , and 3 weeks of treatment , there were no statistically significant differences between both groups .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "both groups", "negation": "negated", "UMLS": {}, "start": 34, "end": 45}], "Outcome": [{"term": "smell scores", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 25}], "Observation": [{"term": "statistically significant differences", "negation": "negated", "UMLS": {}, "start": 112, "end": 149}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "statistically significant differences", "Outcome": "smell scores", "Count": ""}]}, {"Section": "RESULTS", "Text": "In group I , ( 62 % ) of patients completely recovered their sense of smell after 3 weeks of treatment , compared to ( 52 % ) of patients in group II ( P = 0.31 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "group I", "negation": "affirmed", "UMLS": {}, "start": 3, "end": 10}], "Outcome": [{"term": "sense of smell", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 75}], "Observation": [{"term": "completely recovered", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 54}], "Count": [{"term": "( 62 % ) of", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 24}, {"term": "( 52 % )", "negation": "affirmed", "UMLS": {}, "start": 117, "end": 125}]}, "Evidence Propositions": [{"Intervention": "group I", "Observation": "completely recovered", "Outcome": "sense of smell", "Count": ""}]}, {"Section": "CONCLUSION", "Text": "The results suggested that using mometasone furoate nasal spray as a topical corticosteroid in the treatment of post COVID-19 anosmia offers no superiority benefits over the olfactory training , regarding smell scores , duration of anosmia , and recovery rates .", "Evidence Elements": {"Participant": [{"term": "post COVID-19 anosmia", "negation": "affirmed", "UMLS": {}, "start": 112, "end": 133}], "Intervention": [{"term": "mometasone furoate nasal spray", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 63}, {"term": "olfactory training", "negation": "negated", "UMLS": {}, "start": 174, "end": 192}], "Outcome": [{"term": "smell scores", "negation": "negated", "UMLS": {}, "start": 205, "end": 217}, {"term": "duration of anosmia", "negation": "negated", "UMLS": {}, "start": 220, "end": 239}], "Observation": [{"term": "superiority benefits", "negation": "negated", "UMLS": {}, "start": 144, "end": 164}], "Count": []}, "Evidence Propositions": [{"Intervention": "mometasone furoate nasal spray", "Observation": "superiority benefits", "Outcome": "smell scores", "Count": ""}, {"Intervention": "mometasone furoate nasal spray", "Observation": "superiority benefits", "Outcome": "duration of anosmia", "Count": ""}, {"Intervention": "olfactory training", "Observation": "superiority benefits", "Outcome": "smell scores", "Count": ""}, {"Intervention": "olfactory training", "Observation": "superiority benefits", "Outcome": "duration of anosmia", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "TRIAL REGISTRATION : ClinicalTrials.gov ID : NCT04484493 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2021 Elsevier Inc . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}